Development of the Japanese version of functional assessment of cancer therapy-biological response modifier (FACT-BRM)

Atsushi Aruga*, Kojiro Shimozuma, Masanori Terashima, Koji Kono, Etsuko Aruga, David Cella, Sonya Eremenco, Hideaki Tahara

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

1 Scopus citations

Abstract

To assess the quality of life (QOL) in cancer patients who received biological therapy, the Japanese Version of the Functional Assessment of Cancer Therapy-Biological Response Modifier (FACT-BRM) was developed through an iterative forward-backward translation sequence used throughout the FACIT Translation Project Procedures and Guidelines. The pilot testing of the Japanese version of FACT-BRM was done for 15 patients (9 men; 6 women) with the patients who received biological therapy in Japan. Their age ranged from 36 to 81. Eight patients had a performance status (PS) of 0, 6 had a PS of 1, and 1 had a PS of 3. Questionnaire items were found easy to understand, and none were irrelevant or offensive. After the analysis of the results of the pilot study, the Japanese version of the FACT-BRM was finalized. Reliability and validity of the FACT-BRM remain to be evaluated, and the Japanese version of FACT-BRM can be an effective tool to measure QOL in cancer patients receiving biological therapy.

Original languageEnglish (US)
Pages (from-to)217-222
Number of pages6
JournalBiotherapy
Volume20
Issue number2
StatePublished - Mar 1 2006

Keywords

  • Biotherapy
  • FACT-BRM
  • Outcomes
  • Quality of life

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Development of the Japanese version of functional assessment of cancer therapy-biological response modifier (FACT-BRM)'. Together they form a unique fingerprint.

Cite this